0001209191-20-051034.txt : 20200917
0001209191-20-051034.hdr.sgml : 20200917
20200917191047
ACCESSION NUMBER: 0001209191-20-051034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200916
FILED AS OF DATE: 20200917
DATE AS OF CHANGE: 20200917
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Riker Lauren Bullaro
CENTRAL INDEX KEY: 0001545439
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 201182317
MAIL ADDRESS:
STREET 1: C/O PACIRA PHARMACEUTICALS, INC.
STREET 2: 5 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-16
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001545439
Riker Lauren Bullaro
C/O PACIRA BIOSCIENCES, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
0
1
0
0
Vice President, Finance
Common Stock
2020-09-16
4
M
0
3000
10.81
A
16181
D
Common Stock
2020-09-16
4
S
0
3000
60.34
D
13181
D
Stock Option (Right to Buy)
10.81
2020-09-16
4
M
0
3000
0.00
D
2022-06-05
Common Stock
3000
20820
D
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.975 to $60.88, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.
/s/ Kristen Williams, Attorney-in-Fact
2020-09-17